Back to Search
Start Over
A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.
- Source :
- Journal of Neurology, Neurosurgery & Psychiatry; May1987, Vol. 50 Issue 5, p511-516, 6p, 2 Charts, 2 Graphs
- Publication Year :
- 1987
-
Abstract
- A randomised double-blind, placebo-controlled trial of high-dose, pulsed intravenous methylprednisolone was carried out in 50 individuals with multiple sclerosis; 22 patients were in acute relapse and 28 had chronic progressive disease. After a baseline assessment using the Kurtzke functional and expanded disability status scales each patient was randomly allocated to intravenous treatment with methylprednisolone (500 mg) or a saline placebo administered as a single daily dose for 5 days. Clinical assessments were repeated at 1 and 4 weeks after starting treatment. The results from all 50 patients showed a highly significant effect in favour of methylprednisolone treatment (p less than 0.001). In patients with relapse, there was a significant decrease in clinical disability scores at 1 and 4 weeks in the methylprednisolone treated group compared with controls (p less than 0.05 for each comparison). In the chronic progressive group, disability scores at 4 weeks only were significantly lower after treatment with methylprednisolone (p less than 0.01), mainly attributable to improvement in pyramidal function. [ABSTRACT FROM AUTHOR]
- Subjects :
- METHYLPREDNISOLONE
COMPARATIVE studies
FUNCTIONAL assessment
DOSE-effect relationship in pharmacology
RESEARCH methodology
MEDICAL cooperation
MULTIPLE sclerosis
RESEARCH
STATISTICAL sampling
VISUAL evoked response
EVALUATION research
RANDOMIZED controlled trials
BLIND experiment
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 00223050
- Volume :
- 50
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Journal of Neurology, Neurosurgery & Psychiatry
- Publication Type :
- Academic Journal
- Accession number :
- 66071821